Main Outcome Measures
Abbreviations and Acronyms:AMD ( age-related macular degeneration), AREDS ( Age-Related Eye Disease Study), ARMS2 ( age-related maculopathy susceptibility 2), CFH ( complement factor H), df ( degree of freedom), SNP ( single nucleotide polymorphism)
- Causes and prevalence of visual impairment among adults in the United States.Arch Ophthalmol. 2004; 122: 477-485
- A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8.Arch Ophthalmol. 2001; 119: 1417-1436
- Smoking and age-related macular degeneration. The POLA Study.Arch Ophthalmol. 1998; 116: 1031-1035
- Risk factors for the incidence of advanced age-related macular degeneration in the Age-Related Eye Disease Study (AREDS): AREDS report no. 19.Ophthalmology. 2005; 112: 533-539
- The relationship of dietary omega-3 long-chain polyunsaturated fatty acid intake with incident age-related macular degeneration: AREDS report no. 23.Arch Ophthalmol. 2008; 126: 1274-1279
- The relationship of dietary carotenoid and vitamin A, E, and C with age-related macular degeneration in a case-control study: AREDS report no. 22.Arch Ophthalmol. 2007; 125: 1225-1232
- Progression of age-related macular degeneration: association with body mass index, waist circumference, and waist-hip ratio.Arch Ophthalmol. 2003; 121: 785-792
- Blood pressure, atherosclerosis, and the incidence of age-related maculopathy: the Rotterdam Study.Invest Ophthalmol Vis Sci. 2003; 44: 3771-3777
- Long-term blood pressure and age-related macular degeneration: the ALIENOR study.Invest Ophthalmol Vis Sci. 2013; 54: 1905-1912
- Seven new loci associated with age-related macular degeneration.Nat Genet. 2013; 45: 433-439
- Pharmacogenomics of breast cancer therapy: an update.Pharmacol Ther. 2013; 139: 1-11
- The clinically relevant pharmacogenomic changes in acute myelogenous leukemia.Pharmacogenomics. 2012; 13: 1257-1269
- Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab.Ophthalmology. 2007; 114: 2168-2173
- Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab.Br J Ophthalmol. 2009; 93: 610-613
- The influence of genetics on response to treatment with ranibizumab (Lucentis) for age-related macular degeneration: the Lucentis Genotype Study (an American Ophthalmological Society thesis).Trans Am Ophthalmol Soc. 2011; 109: 115-156
- Complement factor H Y402H gene polymorphism and response to intravitreal bevacizumab in exudative age-related macular degeneration.Acta Ophthalmol. 2011; 89 ([report online]): e344-e349
- Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age-related macular degeneration.Retina. 2012; 32: 4-9
- Pharmacogenetics for genes associated with age-related macular degeneration in the comparison of AMD treatments.Ophthalmology. 2013; 120: 593-599
- Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration.Surv Ophthalmol. 2014; 59: 1-18
- CFH and LOC387715/ARMS2 genotypes and treatment with antioxidants and zinc for age-related macular degeneration.Ophthalmology. 2008; 115: 1019-1025
- CFH and ARMS2 genetic polymorphisms predict response to antioxidants and zinc in patients with age-related macular degeneration.Ophthalmology. 2013; 120: 2317-2323
- The Age-Related Eye Disease Study (AREDS): design implications. AREDS report no. 1.Control Clin Trials. 1999; 20: 573-600
- Genetic variants near TIMP3 and high-density lipoprotein-associated loci influence susceptibility to age-related macular degeneration.Proc Natl Acad Sci U S A. 2010; 107: 7401-7406
- An integrated map of genetic variation from 1,092 human genomes.Nature. 2012; 491: 56-65
- Age-related macular degeneration: genetics and biology coming together.Annu Rev Genomics Hum Genet. 2014; 15: 151-171
∗Supplemental material is available at www.aaojournal.org.
Financial Disclosure(s): The author(s) have made the following disclosure(s):
Albert O. Edwards: Patent royalties—University of Michigan, Ann Arbor, Michigan.
Anand Swaroop: Patent royalties—University of Michigan, Ann Arbor, Michigan.
Lars G. Fritsche: Patent royalties—University of Regensburg, Regensburg, Germany (for age-related macular degeneration testing).
Gonçalo R. Abecasis: Consultancy—Regeneron; Patent royalties—University of Michigan, Ann Arbor, Michigan.
Supported by the National Eye Institute/National Institutes of Health , (contract no.: HHS-NOI-EY-0-2127), Bethesda Maryland. The sponsor and funding organization participated in the design and conduct of the study; data collection, management, analysis, and interpretation; and the preparation, review, and approval of the manuscript. The NIH holds a royalty-bearing license issued to Bausch & Lomb for the Age-Related Eye Disease Study Supplement. The Age-Related Eye Disease Study was a clinical trial that was conducted before the required clinical trials registration.